Study highlights the role of high cholesterol in SARS-CoV-2 infectivity

Viking Ther­a­peu­tics tout­ed ear­ly-stage obe­si­ty da­ta show­ing its oral GLP-1/GIP dual ag­o­nist pro­duced 5.3% weight loss and few side ef­fects, send­ing the com­pa­ny’s stock $VK­TX

No­vo Nordisk is ramp­ing up its le­gal cam­paign against med­ical spas, phar­ma­cies and clin­ics mar­ket­ing com­pound­ed ver­sions of its pop­u­lar weight loss and di­a­betes drugs